Table 3.

Clinical parameters of the experimental VR group and the control group before and after the intervention.

Parameter			Experimental VRa group (n=31)		Control group (n=26)
FMA-UEb scorec, mean (SD); (range)
	Pretreatment	27.68 (18.29); 4-63		27.69 (19.92); 6-65
	3 weeks’ treatment	31.87 (19.42); 8-64		31.54 (19.96); 10-66
	3 months	35.90 (21.19); 8-66		35.88 (19.95); 12-66
	6 months	38.06 (21.48); 13-66		38.19 (19.01); 14-66
BId scoree, mean (SD); (range)
	Pretreatment	50.65 (25.10); 10-100		60.77 (24.85); 20-100
	3 weeks’ treatment	64.52 (26.86); 25-100		69.62 (24.41); 25-100
	3 months	72.90 (22.67); 30-100		75.96 (23.20); 25-100
	6 months	77.90 (20.55); 30-100		81.73 (19.95); 35-100
IADLf scoreg, mean (SD); (range)
	Pretreatment	2.65 (1.99); 0-8		2.46 (2.13); 1-7
	3 weeks’ treatment	3.16 (2.30); (0-8)		3.12 (1.97); 1-7
	3 months	3.90 (2.53); 0-8		3.69 (2.33); 1-8
	6 months	4.52 (2.94); 0-8		4.73 (2.28); 1-8

^aVR: virtual reality.

^bFMA-UE: Fugl-Meyer Assessment for Upper Extremity.

^cTwo-way ANOVA: time, P<.001 (significant); treatment, P=.99; treatment × time, P=.95.

^dBI: Barthel Index.

^eTwo-way ANOVA: time, P<.001 (significant); treatment, P=.34; treatment × time, P=.32.

^fIADL: instrumental activities of daily living.

^gTwo-way ANOVA: time, P<.001 (significant); treatment, P=.92; treatment × time, P=.81.